Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Cediranib Plus Cisplatin and Fluoropyrimidine in Japanese Patients With Unresectable Gastric Cancer
jRCT2080220881Phase 1
- Sponsor
- AstraZeneca
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cediranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by AstraZeneca.
02
Drugs
cediranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080220881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220881.